1 in 4 Americans will develop heart failure | Nasal spray approved for CHF-related edema | New data on semaglutide & tirzepatide

Approximately one in four Americans will develop heart failure in their lifetime, according to a new report from the Heart Failure Society of America. What can be done to combat this worrisome trend?

The newly approved intranasal loop diuretic can also be used to treat edema in patients with liver and kidney disease.

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Most patients are first diagnosed with heart failure in an emergency room or hospital, when their symptoms are already severe. This advanced algorithm could change all that by opening up screening to many more patients. 

New HFSA recommendations highlight the importance of integrating palliative care into the day-to-day care of heart failure patients.

Finerenone, sold by Bayer under the brand name Kerendia, is now approved in the United States for the treatment of HFmrEF and HFpEF. The drug has already been used for years to treat patients with chronic kidney disease and type 2 diabetes.